NCT04126733 - Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 14, 2019

Primary Completion Date

November 11, 2020

Study Completion Date

March 28, 2022

Conditions

Colorectal Cancer

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

Regorafenib administered as oral tablets given every day for 3 weeks of each 28 days treatment cycle (i.e., 3 weeks on, 1 week off)

BIOLOGICAL

Nivolumab (Opdivo)

Administered on day 1 of every treatment cycle.

Trial Locations (15)

12206

New York Oncology Hematology. P.C., Albany

23606

Virginia Oncology Associates, Newport News

33176

Miami Cancer Institute at Baptist Health South Florida, Miami

37203

Sarah Cannon Cancer Center, Nashville

55404

Minnesota Oncology Hematology, PA, Minneapolis

60005

Illinois Cancer Specialists, Arlington Heights

68046

Nebraska Cancer Specialists, Papillion

75090

Texas Oncology-Sherman, Sherman

75246

Baylor Charles A. Sammons Cancer Center at Dallas, Dallas

76012

Texas Oncology-Arlington North, Arlington

77030

University of Texas MD Anderson Cancer Center, Houston

80218

Rocky Mountain Cancer Centers, Denver

91010

City of Hope National Medical Center, Duarte

97401

Willamette Valley Cancer Institute and Research Center, Eugene

98684

Northwest Cancer Specialists, PC, Vancouver